AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.

Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for ...

Global ISO experts, Amtivo Group, is delighted to announce the relaunch of its website dedicated to ISO 9001, together with a ...

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placeboAchieved statistical significance on key secondary ...

As of February 7 at 3:33:35 p.m. EST. Market Open.

H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the shares ...

AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ...

H.C. Wainwright analyst Emily Bodnar increased the price target on AnaptysBio (NASDAQ:ANAB) shares to $22.00, up from the previous $19.00, while maintaining a Neutral rating on the stock. According to ...

Here’s everything you need to know. Yahoo Finance is launching a new column called “Ask a Realtor.” Five Realtors from around the U.S. answer reader questions about buying, selling ...

Yahoo Finance anchor Julie Hyman outlines the top stories on Wall Street on today's Market Minute. Intel (INTC) shares gained after US Vice President JD Vance highlighted the importance of US ...